Objective To analyze nosocomial infection and drug resistance of Acinetobacter baumannii in our hospital from January 2018 to December 2022,and to provide evidence for nosocomial infection prevention and control deployment in our hospital and clinical standard drug use.Methods Clinical data of Acinetobacter baumannii isolated from patients hospitalized in the Third People's Hospital of Hangzhou Xiaoshan District from January 2018 to December 2022,such as detection rate,specimen source,patient age,ward distribution and drug sensitivity rest.Results The average detection rate of Acinetobacter baumannii in 540 cases was 6.48%for the past 5 years.The main source of Acinetobacter baumannii was sputum in 375 cases(69.44%),followed by pharyngeal swab in 131 cases(24.26%).The age of the patients was concentrated in 266 cases(49.26%)between 71 and 90 years old,followed by 107 cases(19.81%)between 0 and 10 years old.From the perspective of department distribution,the main area of Acinetobacter baumannii was in ICU162 cases(30.00%),respiratory medicine 131 cases(24.26%)and pediatrics111 cases(20.56%).Acinetobacter baumannii had a high resistance rate to cefazolin,ampicillin,furantoin and cefotetan,approaching 100%.The resistance rate of cotrimoxazole was from 6.59%in 2018 to 20.16%in 2022,which showed a continuous upward trend in the past 5 years.Imipenem,ciprofloxacin,gentamicin,tobramycin,ceftazidime,ampicillin/sulbactam,ceftriaxone,cefepime,and aztreonam reached their highest resistance rates in 2019,and showed a significant downward trend in 2020,2021 and 2022.Conclusion Acinetobacter baumannii is mainly isolated from respiratory specimens of elderly and children.It is necessary to focus on monitoring the ICU,respiratory medicine and pediatrics of our hospital.The clinical standard application of antibiotics according to the drug susceptibility results and strict prevention and control of hospital illness can reduce the risk of multi-drug resistant infection and transmission of Acinetobacter baumannii.
万方数据
维普
